Placebo News and Research

RSS

Omalizumab fast, safe and well-tolerated in teens and adults with chronic spontaneous urticaria

An international team of researchers has found that a once-a-month, high-dose injection of a commonly used asthma drug is highly effective in treating teens and adults chronically afflicted with hives and severe, itchy rash. The drug, omalizumab, was tested on 323 people at 55 medical centers for whom standard antihistamine therapy failed to quell their underlying, allergy-like reaction, known as chronic idiopathic urticaria or chronic spontaneous urticaria.

25 Feb 2013

Ampio to initiate dose escalation run-in study for treatment of knee osteoarthritis

Ampio Pharmaceuticals, Inc. announced today that it's Phase III clinical study of Ampion™ for the treatment for osteoarthritis of the knee will include a dose-escalation run-in study as recommended by the FDA.

25 Feb 2013

New data from Boehringer Ingelheim's tiotropium Respimat Phase III UniTinA-asthma programme

Tiotropium delivered once daily via Respimat significantly improved lung function and reduced asthma exacerbations in patients who remain symptomatic despite treatment with at least ICS/LABA, irrespective of their allergic status.

24 Feb 2013

Florida Hospital Pepin Heart Institute, USF partner for novel gene therapy trial

Cardiovascular disease specialists at Florida Hospital Pepin Heart Institute and Dr. Kiran C. Patel Research Institute affiliated with the University of South Florida announced they have enrolled their first patients into a clinical trial testing a novel gene therapy for the treatment of heart failure after ischemic injury. The therapy may promote the regeneration of heart tissue by encouraging the body to deploy more stem cells to the injury site.

22 Feb 2013

Selenium supplements and heart disease risk: an interview with Dr Saverio Stranges, University of Warwick

Selenium is a micronutrient which has antioxidant properties by means of selenoproteins which play many important functions in the body. They actually are contained in many different foods. The amount of selenium we get from diet is closely linked to the amount of selenium in the soil.

21 Feb 2013

NIAID-funded Phase I trial to evaluate two related candidate vaccines against shigellosis

Researchers have launched an early-stage human clinical trial of two related candidate vaccines to prevent infection with Shigella, bacteria that are a significant cause of diarrheal illness, particularly among children.

21 Feb 2013

Immune Pharmaceuticals commences Phase II study with bertilimumab to treat ulcerative colitis

Immune Pharmaceuticals Ltd., a privately held Israeli company, and EpiCept Corporation announced today that Immune is initiating, following authorization from Israeli health authorities, a Phase II double-blind placebo controlled study with its lead drug, bertilimumab, in patients with moderate-to-severe ulcerative colitis.

21 Feb 2013

Dabigatran decreases risk of recurrent venous thromboembolism

New findings from two double-blind, randomized trials, RE-MEDY and RE-SONATE, show that dabigatran 150 mg twice daily reduces the risk of recurrent venous thromboembolism (VTE).

21 Feb 2013

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

UCB announced today two new regulatory filings with the US Food and Drug Administration (FDA) and with the European Medicines Agency (EMA) to extend the marketing authorization for Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis (PsA) and for adult patients with active axial spondyloarthritis (axSpA).

20 Feb 2013

Dog owners concerned about daily living with osteoarthritis

Carprofen for the treatment of dogs with osteoarthiritis significantly improves owner-assessed chronic pain as well as lameness compared with placebo, show US study results.

20 Feb 2013

Predictive value of prostate cancer gene 3 validated

Researchers have confirmed that the prostate cancer gene 3 is a valid predictor for current cancer and future biopsy outcomes.

20 Feb 2013

Mouthrinse use associated with reduced plaque and gingivitis

New research published in the January/February 2013 issue of General Dentistry, the peer-reviewed clinical journal of the Academy of General Dentistry (AGD), indicates that the use of a germ-killing mouthrinse in addition to regular toothbrushing can significantly reduce plaque and gingivitis, more so than brushing alone.

20 Feb 2013

Meloxicam recognizes and treats osteoarthritis in cats

Scientists at the University of Montreal's Quebec Research Group in Animal Pharmacology have found a way to recognize and treat osteoarthritis in cats - a condition that the owner might not notice and that can make even petting painful.

20 Feb 2013

Oxidative stress: the price of sucrose pain relief in neonates

Although sucrose significantly reduces the pain experienced by preterm neonates undergoing heel lance, it is associated with significant increases in adenosine triphosphate use and oxidative stress, the results of a US study indicate.

19 Feb 2013

Antimuscarinic effective for overactive bladder in elderly

The antimuscarinic drug fesoterodine seems to be an effective and well-tolerated treatment for elderly individuals with an overactive bladder, including those older than 75 years, show findings from a clinical trial.

19 Feb 2013

Positive results from Neurim’s Piromelatine phase II study on insomnia

Neurim Pharmaceuticals announced today positive results from a phase II clinical study evaluating the efficacy and safety of Piromelatine (Neu-P11), a novel investigational multimodal sleep medicine developed for the treatment of patients with primary and co-morbid insomnia.

18 Feb 2013

Patients with untreated depression are poorly protected by shingles vaccination

Results from a new study published in Clinical Infectious Diseases suggest a link between untreated depression in older adults and decreased effectiveness of the herpes zoster, or shingles, vaccine.

16 Feb 2013

Positive new data from Genzyme’s eliglustat tartrate Phase 3 studies on Gaucher disease type 1

Genzyme, a Sanofi company, today announced positive new data from the Phase 3 ENGAGE and ENCORE studies of eliglustat tartrate, its investigational oral therapy for Gaucher disease type 1.

15 Feb 2013

Researchers identify new molecular pathway involved in alveoli growth

In a study of mice, researchers at Johns Hopkins have identified a new molecular pathway involved in the growth of tiny air sacs called alveoli that are crucial for breathing. The scientists say their experiments may lead to the first successful treatments to regrow the air sacs in people who suffer from diseases such as emphysema in which the air sacs have been destroyed by years of smoking.

15 Feb 2013

Dompé initiates enrollment in rhNGF phase I/II REPARO study for neurotrophic keratitis

The first patient has been enrolled in the phase I/II REPARO study, the first international clinical trial evaluating the ophthalmological use of a topical solution of recombinant human Nerve Growth Factor (rhNGF) for the treatment of moderate to severe neurotrophic keratitis (NK).

15 Feb 2013

Placebo News and Research

Omalizumab fast, safe and well-tolerated in teens and adults with chronic spontaneous urticaria

Ampio to initiate dose escalation run-in study for treatment of knee osteoarthritis

New data from Boehringer Ingelheim's tiotropium Respimat Phase III UniTinA-asthma programme

Florida Hospital Pepin Heart Institute, USF partner for novel gene therapy trial

Selenium supplements and heart disease risk: an interview with Dr Saverio Stranges, University of Warwick

NIAID-funded Phase I trial to evaluate two related candidate vaccines against shigellosis

Immune Pharmaceuticals commences Phase II study with bertilimumab to treat ulcerative colitis

Dabigatran decreases risk of recurrent venous thromboembolism

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

Dog owners concerned about daily living with osteoarthritis

Predictive value of prostate cancer gene 3 validated

Mouthrinse use associated with reduced plaque and gingivitis

Meloxicam recognizes and treats osteoarthritis in cats

Oxidative stress: the price of sucrose pain relief in neonates

Antimuscarinic effective for overactive bladder in elderly

Positive results from Neurim’s Piromelatine phase II study on insomnia

Patients with untreated depression are poorly protected by shingles vaccination

Positive new data from Genzyme’s eliglustat tartrate Phase 3 studies on Gaucher disease type 1

Researchers identify new molecular pathway involved in alveoli growth

Dompé initiates enrollment in rhNGF phase I/II REPARO study for neurotrophic keratitis

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News